Figure 6
![Figure 6. CD19-CAR–modified TSCM mediate long-lasting antitumor responses. (A) In vivo bioluminescent imaging, (B) radiance, and (C) survival of NSG mice bearing systemic NALM6-GL leukemia xenografts after adoptive transfer of CD19-CAR–modified standard or TSCM-enriched CD8+ T cells (2.5 × 105) in conjunction with intraperitoneal injections of recombinant human IL-15 every other day (****P < .0001; log-rank [Mantel-Cox]; n = 5). Data shown are representative of 2 independent experiments. d, day.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/128/4/10.1182_blood-2015-11-683847/4/519f6.jpeg?Expires=1722421359&Signature=IeyxBfh2DYiUcby5SGunlh3YuH7gICgi4X~j1HWDGwToSusVs0aFxUDes97nSanVSubSJbsoCUFEjgLibZSA2HcYCve~Fd8D~HRIw9-lAEeAyGUaD8G1pJmWEn6zRPrCFlBg27nOpwGEhh1j0Q8cgCU79hbNBbH~Remz~NcxWpk3F8GadEN7mZgHORGAz79L5dTbCsjehgfzFRD5BILHGDhMfhcxUa1RTllhwpMoYVV19T3XcwhFlA0JsI1ct6bXzIGLJeYAsvqz8y8vINsAyNA3UlCqyEfoX2RxawXDxQf51rGwSieYVUKUKG6LyWIHfUhFwtrwwolLcO3mp4tFCw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
CD19-CAR–modified TSCM mediate long-lasting antitumor responses. (A) In vivo bioluminescent imaging, (B) radiance, and (C) survival of NSG mice bearing systemic NALM6-GL leukemia xenografts after adoptive transfer of CD19-CAR–modified standard or TSCM-enriched CD8+ T cells (2.5 × 105) in conjunction with intraperitoneal injections of recombinant human IL-15 every other day (****P < .0001; log-rank [Mantel-Cox]; n = 5). Data shown are representative of 2 independent experiments. d, day.
